Skip to main content

REVIEW article

Front. Oncol.

Sec. Cancer Metabolism

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1564419

Progress of Arylacetamide Deacetylase Research in Metabolic Diseases

Provisionally accepted
Liu Yang Liu Yang Zhe-Zhen Liao Zhe-Zhen Liao Xin-Hua Xiao Xin-Hua Xiao *Li Ran Li Ran *
  • The First Affiliated Hospital, University of South China, Hengyang, China

The final, formatted version of the article will be published soon.

    Arylacetamide deacetylase (AADAC), a microsomal serine esterase belonging to the polygenic hydrolase family, is predominantly localized in the liver and intestine. It plays a significant role in drug metabolism, lipid metabolism, and the pathogenesis of various diseases. In the context of drug metabolism, AADAC is vital for ensuring the safety of ester-based drugs. Its substrate specificity for short-chain acyl groups, along with genetic polymorphisms among individuals and species, influences drug-related processes. Regarding lipid metabolism, The lipase activity of AADAC is involved in the hydrolysis of cholesterol and triglycerides, lipid mobilization, and the assembly of lipoproteins. The expression of AADAC is regulated by multiple factors. It is associated with metabolic disorders; for instance, its decreased expression in the liver during obesity may impact triglyceride metabolism, and it may also have an indirect role in diabetes. In cardiovascular diseases, AADAC holds potential as a diagnostic marker. Its role in cancer is heterogeneous, being downregulated in certain cancers while upregulated in others, such as pancreatic and ovarian cancers, where it acts to inhibit cancer progression. Within the nervous system, AADAC may influence neurotransmitter regulation and drug metabolism. Currently, research on AADAC agonists is limited, and the development of inhibitors presents challenges, underscoring the necessity for further investigation in this area.

    Keywords: AADAC, Metabolic Diseases, Structure, drug metabolism, Lipid Metabolism, Obesity, diabetes, Cancer. (Min.5-Max. 8

    Received: 22 Jan 2025; Accepted: 31 Mar 2025.

    Copyright: © 2025 Yang, Liao, Xiao and Ran. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xin-Hua Xiao, The First Affiliated Hospital, University of South China, Hengyang, China
    Li Ran, The First Affiliated Hospital, University of South China, Hengyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more